Rekombinanter CD19 (Inebilizumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter CD19 (Inebilizumab Biosimilar) Antikörper (ABIN7581284)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-CD19 Reference Antibody (inebilizumab)
-
Produktmerkmale
- Anti-CD19 Reference Antibody (inebilizumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 147.42 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Conditions: B-cell malignancies Chronic Lymphocytic Leukemia Multiple Myeloma Neuromyelitis optica spectrum disorder Scleroderma
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- CD19 (Inebilizumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Molekulargewicht
- 147.42 kDa
-
UniProt
- P15391
Target
-